Actively Recruiting
Open-label Trial to Evaluate Safety and Initial Effectiveness of Oral TGRX-678 for Chronic Myeloid Leukemia Patients Resistant or Intolerant to TKI Treatments
Led by Shenzhen TargetRx Co., Ltd. · Updated on 2026-10-20
90
Participants Needed
2
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying TGRX-678 in patients with Chronic Myelogenous Leukemia CML who have either not responded to or cannot tolerate tyrosine kinase inhibitor TKI treatments. This early-phase, open-label trial focuses on assessing the safety, tolerability, and initial effectiveness of TGRX-678 in advanced or resistant CML cases. The study aims to determine the best dose for future research based on safety, drug behavior, and efficacy. Participants receive TGRX-678 tablets orally once daily at doses adjusted through a dose escalation and expansion design. The trial includes a dose escalation phase to find the recommended dose for expansion RDE and continues into a cohort expansion phase to further evaluate safety and efficacy. This study is conducted over an average of two years, with ongoing monitoring for adverse events and drug levels in the body. During the study, participants undergo regular blood tests to monitor blood cell counts, disease markers, and drug levels at specific times throughout treatment cycles, each lasting 28 days. Safety is closely observed during the first cycle and throughout the study. The main outcomes measured include the recommended dose for further trials, safety profiles, and changes in hematologic, cytogenetic, and molecular responses. Participants are involved in frequent assessments during treatment to evaluate the drugs impact and tolerability.
CONDITIONS
Brief Title
TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
Research Team
X
Xinyi Zhu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here